Company newsMRNA
Explain this story: Guggenheim raises BlossomHill Therapeutics price target to $40 on pipeline progress By Investing.com
Guggenheim has increased its price target for BlossomHill Therapeutics (NASDAQ: BLSM) to $40 from $30, maintaining a Buy rating, following promising pipeline advancements for its lead asset BH-30643 in lung cancer treatment. The company also reported strong Q2 2026 results and has a robust cash position, with $95 million in cash and equivalents and $168 million from its August 2026 IPO, extending its cash runway beyond major clinical readouts. JPMorgan also initiated coverage with an Overweight rating and a $28 price target, indicating growing confidence in the company's potential.
OtherInvesting.com South AfricaSector and industry: HealthcareBiotechnologyTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Guggenheim has increased its price target for BlossomHill Therapeutics (NASDAQ: BLSM) to $40 from $30, maintaining a Buy rating, following promising pipeline advancements for its lead asset BH-30643 in lung cancer treatment. The company also reported strong Q2 2026 results and has a robust cash position, with $95 million in cash and equivalents and $168 million from its August 2026 IPO, extending its cash runway beyond major clinical readouts. JPMorgan also initiated coverage with an Overweight rating and a $28 price target, indicating growing confidence in the company's potential.
Article tone: Positive This describes the words the journalist used. It is not a prediction, and not advice.